GlassScriptPhysician profile
Grace Y Kim
NPI 1750525606
$4,657.63
in general payments reported to CMS, 2019-2025
21 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $410 · 2021: $236 · 2022: $245 · 2023: $587 · 2024: $1,747 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990 · Travel and Lodging: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.75 |
| Travel and Lodging | $942.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,834.03 | 2023-2025 | Minimed 780g, Mycarelink |
| Amgen INC. | $316.79 | 2021-2025 | Prolia, Evenity |
| Novo Nordisk INC | $278.25 | 2019-2020 | |
| Dexcom, INC. | $260.08 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $222.26 | 2019-2021 | |
| Medtronic Minimed, INC. | $205.82 | 2019-2020 | |
| Insulet Corporation | $205.35 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $183.90 | 2021-2022 | |
| Lilly USA, LLC | $181.69 | 2019-2022 | |
| Abbvie INC. | $167.09 | 2023-2024 | |
| Sequel Med Tech, LLC | $149.99 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $146.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $123.81 | 2020 | |
| Mannkind Corporation | $93.74 | 2019 | |
| Radius Health, INC. | $92.30 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $75.48 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Senseonics, Incorporated | $39.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.05 | 2023 | Nuzyra |
| Ultragenyx Pharmaceutical INC. | $22.47 | 2023 | |
| Opko Pharmaceuticals, LLC | $18.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.89 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.